Literature DB >> 26046002

Association between WT1 polymorphisms and susceptibility to breast cancer: results from a case-control study in a southwestern Chinese population.

Xiao-Wei Qi1, Xiao-Dong Zheng2, Bei-Ge Zong3, Qing-Qiu Chen3, Fan Zhang3, Xin-Hua Yang3, Yi Zhang3, Jun-Lan Liu3, Jun Jiang3.   

Abstract

Wilms' tumor gene 1 (WT1) single nucleotide polymorphism (SNP), rs16754, has been considered as an independent prognostic factor in patients with acute myeloid leukemia and renal cell carcinoma. However, its biological role in breast cancer has not been reported. To test whether WT1 SNPs can be used as a molecular marker in order to improve the risk stratification of breast cancer, we performed a case-control study including 709 female sporadic breast cancer patients and 749 female healthy control subjects in the Southeast China. Five WT1 SNPs (rs16754, rs3930513, rs5030141, rs5030317, rs5030320) were selected and determined by polymerase chain reaction-ligase detection reaction to assess their associations with breast cancer risk. Results showed the distributions of the alleles of these WT1 SNPs were consistent with data from Chinese population as suggested by the International HapMap Project. Individuals with the minor alleles of rs16754, rs5030317 and rs5030320 showed a significant decrease of breast cancer risk in codominant model (OR = 0.6370, 95% CI: 0.4260-0.9520 for rs16754; OR = 0.5940, 95% CI: 0.3890-0.9070 for rs5030317; OR = 0.5870, 95% CI: 0.3850-0.8960 for 5030320, respectively) and recessive model. Stratified analyses showed the protective effects were more evident in the subjects with age ≤ 50 years or in pre-menopausal status. To explore the potential mechanism, we conducted bioinformatics genotype-phenotype correlation analysis, and found that the mRNA expression level for homozygous rare allele of WT1 gene was lower than that in wild-type and heterozygous group (P = 0.0021) in Chinese population. In summary, our findings indicated that minor alleles of rs16754, rs5030317 and rs5030320 are associated with reduced risk of breast cancer, suggesting that WT1 SNPs may be a potential biomarker of individualized prediction of susceptibility to breast cancer. However, large prospective and molecular epidemiology studies are needed to verify this correlation and clarify its underlying mechanisms.

Entities:  

Keywords:  WT1; breast cancer; polymorphism; risk; susceptibility

Year:  2015        PMID: 26046002      PMCID: PMC4449451     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  62 in total

Review 1.  A clinical overview of WT1 gene mutations.

Authors:  M Little; C Wells
Journal:  Hum Mutat       Date:  1997       Impact factor: 4.878

2.  HER2/neu increases the expression of Wilms' Tumor 1 (WT1) protein to stimulate S-phase proliferation and inhibit apoptosis in breast cancer cells.

Authors:  Musaffe Tuna; Arturo Chavez-Reyes; Ana M Tari
Journal:  Oncogene       Date:  2005-02-24       Impact factor: 9.867

Review 3.  Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene.

Authors:  Vicki Huff
Journal:  Nat Rev Cancer       Date:  2011-01-20       Impact factor: 60.716

Review 4.  Breast cancer in China.

Authors:  Lei Fan; Kathrin Strasser-Weippl; Jun-Jie Li; Jessica St Louis; Dianne M Finkelstein; Ke-Da Yu; Wan-Qing Chen; Zhi-Ming Shao; Paul E Goss
Journal:  Lancet Oncol       Date:  2014-06       Impact factor: 41.316

5.  Expression of the Wilms' tumor gene (WT1) in human leukemias.

Authors:  H Miwa; M Beran; G F Saunders
Journal:  Leukemia       Date:  1992-05       Impact factor: 11.528

6.  Mutations in the Wilms' tumor gene WT1 in leukemias.

Authors:  L King-Underwood; J Renshaw; K Pritchard-Jones
Journal:  Blood       Date:  1996-03-15       Impact factor: 22.113

7.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

8.  Wilms' tumour 1 gene expression is increased in hepatocellular carcinoma and associated with poor prognosis.

Authors:  Toshiki Sera; Yoichi Hiasa; Toshie Mashiba; Yoshio Tokumoto; Masashi Hirooka; Ichiro Konishi; Bunzo Matsuura; Kojiro Michitaka; Keiko Udaka; Morikazu Onji
Journal:  Eur J Cancer       Date:  2008-02-05       Impact factor: 9.162

Review 9.  The many facets of the Wilms' tumour gene, WT1.

Authors:  Peter Hohenstein; Nicholas D Hastie
Journal:  Hum Mol Genet       Date:  2006-10-15       Impact factor: 6.150

10.  Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth.

Authors:  Y Oji; H Ogawa; H Tamaki; Y Oka; A Tsuboi; E H Kim; T Soma; T Tatekawa; M Kawakami; M Asada; T Kishimoto; H Sugiyama
Journal:  Jpn J Cancer Res       Date:  1999-02
View more
  2 in total

Review 1.  A systematic review and meta-analysis of the impact of WT1 polymorphism rs16754 in the effectiveness of standard chemotherapy in patients with acute myeloid leukemia.

Authors:  J E Megías-Vericat; M J Herrero; L Rojas; P Montesinos; V Bosó; F Moscardó; D Martínez-Cuadrón; J L Poveda; M Á Sanz; S F Aliño
Journal:  Pharmacogenomics J       Date:  2015-12-08       Impact factor: 3.550

Review 2.  The role of WT1 in breast cancer: clinical implications, biological effects and molecular mechanism.

Authors:  Ye Zhang; Wen-Ting Yan; Ze-Yu Yang; Yan-Ling Li; Xuan-Ni Tan; Jun Jiang; Yi Zhang; Xiao-Wei Qi
Journal:  Int J Biol Sci       Date:  2020-02-24       Impact factor: 6.580

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.